Patents by Inventor Allen Ebens

Allen Ebens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CLL-1 antibodies and methods of use
    Patent number: 11466087
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: October 11, 2022
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • HPV-SPECIFIC BINDING MOLECULES
    Publication number: 20210363258
    Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV16 E6 and HPV16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 25, 2021
    Applicant: Juno Therapeutics, Inc.
    Inventors: James SISSONS, Cameron Brandt, Alexandra Croft, Allen Ebens, Haley Peper, Dean Y. Toy
  • HPV-specific binding molecules
    Patent number: 11072660
    Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: July 27, 2021
    Assignee: Juno Therapeutics, Inc.
    Inventors: James Sissons, Cameron Brandt, Alexandra Croft, Allen Ebens, Haley Peper, Dean Y. Toy
  • Anti-CLL-1 Antibodies and Methods of Use
    Publication number: 20200148774
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Application
    Filed: October 21, 2019
    Publication date: May 14, 2020
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Anti-CLL-1 antibodies and methods of use
    Patent number: 10501545
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: December 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • MHC-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
    Publication number: 20190324030
    Abstract: Provided are methods of identifying peptide epitopes of an antigen recognized by the non-classical major histocompatibility complex (MHC) molecule designated MHC-E. In some embodiments, the antigen is a tumor antigen, autoimmune antigen or pathogenic antigen. Also provided are methods of identifying peptide binding molecules that bind to a peptide in the context of an MHC-E molecule. In some embodiments, the peptide binding molecule is a T cell receptor (TCR) or antibody, including antigen-binding fragments thereof and chimeric antigen receptors (CAR) thereof. Also provided are methods of genetically engineering cells containing such MHC-E-restricted peptide binding molecules, and such genetically engineered cells, including compositions thereof and uses in adoptive cell therapy.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 24, 2019
    Applicant: Juno Therapeutics, Inc.
    Inventors: Semih U. TAREEN, James SISSONS, Mark FROHLICH, Allen EBENS
  • HPV-SPECIFIC BINDING MOLECULES
    Publication number: 20190225692
    Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 25, 2019
    Applicant: Juno Therapeutics, Inc.
    Inventors: James SISSONS, Cameron BRANDT, Alexandra CROFT, Allen EBENS, Haley PEPER, Dean Y. TOY, Brian BELMONT, Stephen GOLDFLESS, Yue JIANG, Timothy JOHNSTONE, David KOPPSTEIN, Hieu NGUYEN, Blythe SATHER, Sonia TIMBERLAKE
  • IMMUNOMODULATORY POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20190194283
    Abstract: Provided herein are immunomodulatory polypeptides containing first and second submits of a cytokine or a chemokine connected by a joining region containing a targeting moiety that binds to a target molecule. In some aspects, the disclosure further relates to engineered cells and compositions comprising the immunomodulatory polypeptides and methods for their administration to subjects. In some embodiments, the cells engineered to contain the immunomodulatory polypeptide, such as T cells, further contain a genetically engineered antigen receptor that specifically binds to antigens, such as a chimeric antigen receptor (CAR). In some embodiments, features of the polypeptides, engineered cells, and methods provide for improved treatment of diseases or disorders, such as by reducing adverse effects of cytokine or chemokine therapy, or increasing activity, efficacy and/or persistence or decreasing immunogenicity of adoptive cell therapy.
    Type: Application
    Filed: July 28, 2017
    Publication date: June 27, 2019
    Applicant: Juno Therapeutics, Inc.
    Inventors: Collin HAUSKINS, Allen EBENS
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR HEMATOPOIETIC ORIGIN
    Publication number: 20170362318
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: January 13, 2017
    Publication date: December 21, 2017
    Inventors: Craig Crowley, Frederic J. De Sauvage, Dan L. Eaton, Allen Ebens, JR., Kristi Elkins, Jo-Anne S. Hongo, Jagath Reddy Junutula, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen, Bing Zheng
  • METHODS OF TREATING HER2-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-HER2 ANTIBODIES
    Publication number: 20170008971
    Abstract: The invention provides compositions and methods for treating HER2-postitive cancers. The method comprising administering a PD-1 axis binding antagonist and an antibody that targets HER2.
    Type: Application
    Filed: June 16, 2016
    Publication date: January 12, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark S. DENNIS, Allen EBENS, Bryan IRVING, Teemu T. JUNTTILA, Ji LI
  • ANTI-CLL-1 ANTIBODIES AND METHODS OF USE
    Publication number: 20160368994
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Application
    Filed: June 14, 2016
    Publication date: December 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Anti-FcRH5 antibodies and immunoconjugates and methods of use
    Patent number: 9360484
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: June 7, 2016
    Assignee: GENENTECH, INC.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Patent number: 9085630
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: July 21, 2015
    Assignee: Genentech, Inc.
    Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebens, Jr., Andrew Poison, Victoria Smith
  • Anti-FcRH5 antibodies and immunoconjugates and methods of use
    Patent number: 9017951
    Abstract: A method of determining the presence of FcRH5 in a biological sample suspected of containing FcRH5 is provided comprising exposing the biological sample to an isolated monoclonal anti-FcRH5 antibody.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: April 28, 2015
    Assignee: Genenech, Inc.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20140106374
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 12, 2013
    Publication date: April 17, 2014
    Applicant: Genentech, Inc.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Anti-FcRH5 antibodies and immunoconjugates and methods of use
    Patent number: 8617559
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: December 31, 2013
    Assignee: Genetech, Inc.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Anti-FcRH5 antibodies and immunoconjugates and methods of use
    Patent number: 8466260
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: June 18, 2013
    Assignee: Genentech, Inc.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Anti-FcRH5 antibodies and immunoconjugates and methods of use
    Patent number: 8362213
    Abstract: Anti-FcRH5 antibodies and immunoconjugates thereof are provided. Methods of using anti-FcRH5 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: January 29, 2013
    Assignee: Genentech, Inc.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN
    Publication number: 20110206658
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: October 12, 2010
    Publication date: August 25, 2011
    Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebens, JR., Kristi Elkins, Jo-Anne S. Hongo, Jagath Reddy Juntula, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen, Bing Zheng
  • ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20110171125
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 14, 2011
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu